Wednesday 12 June 2024

BioLargo Subsidiary Clyra Medical Selects Keystone Industries to Support Manufacturing of its Medical Products

Westminster, CA – June 12, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its subsidiary Clyra Medical Technologies, Inc. (“Clyra”) has selected Keystone Industries, a global manufacturer of medical, dental and cosmetic products with distribution partners in more than 70 countries, to support manufacturing of its medical products. The relationship focuses on the build-out of scaled manufacturing capacity for Clyra’s FDA 510(k) cleared Bioclynse surgical wound irrigation solution. Clyra and Keystone have been and continue to make significant investments to support the launch of Bioclynse.

Bioclynse is Clyra’s FDA 510(k) cleared, safe, highly effective, broad spectrum wound irrigation solution with enormous potential to improve patient outcomes in applications like orthopaedic surgery and dentistry. Advantages of Bioclynse include:

  • Non-cytotoxic, non-sensitizing, no damage to tissue
  • No rinse-out required
  • Non-staining
  • Sustained multi-day efficacy
  • Effective against biofilms

Cary Robinson, President and CEO of Keystone Industries, said, “We are excited to support Clyra Medical Technologies to bring Bioclynse to the market. Keystone has a century of experience in developing and manufacturing medical device, OTC and pharmaceutical products. We have committed a significant investment in our infrastructure to support the manufacturing of innovative products like Clyra’s Bioclynse and can readily provide the needed support to scale up production rapidly.”

Steve Harrison, President of Clyra Medical Technologies, commented, “We are continuing to work hard and spend money to support the scaled roll-out of the Bioclynse surgical wound irrigation solution. Finding a manufacturing partner willing to invest significant money in new equipment and dedicated space was critical to these efforts. We look forward to a long and mutually prosperous relationship with Keystone.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

About Keystone Industries, Inc.

Keystone Industries is a market leader with over 100 years experience in developing cosmetic, medical device, OTC and pharmaceutical products. The company operates through a diverse network of over 800 U.S. and international distribution partners in more than 70 countries. Keystone maintains FDA licensing, ISO 13485 (medical device) and 22716 certifications, as well as GMP certification and international product registrations. Keystone’s commitment to innovation and quality ensures that the company consistently exceed the evolving needs of their customers. See our website at www.keystoneindustries.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Tuesday 11 June 2024

BioLargo Manufactures First Cellinity Battery Cells, a Safer Alternative to Lithium-ion

Westminster, CA – June 11, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that it had succeeded in manufacturing its first CellinityTM “Liquid Sodium” prototype battery cells. Visit www.BioLargoEnergy.com to learn more.













Cellinity is BioLargo’s next-generation battery platform designed to provide safe, environmentally conscious large-format long-duration battery energy storage for applications including grid-scale storage, renewable energy storage, charging stations for electric vehicles, and a variety of other commercial and industrial applications. Cellinity is not a lithium-ion battery – rather, it uses a unique chemistry involving molten salt electrolytes that imparts substantial benefits over lithium-ion chemistry. These newly manufactured Cellinity prototype cells will now be tested and validated for the energy storage and transfer performance claims that were generated in the technology’s early-stage research and development by its original inventors:

  • Far greater safety – no runaway fires, no risk of explosion;
  • Extremely long-lasting – no performance decrease over thousands of cycles;
  • No self-discharging, no out-gassing, and no parasitic load for cooling;
  • High energy density – more energy per unit of weight than lithium batteries;
  • All materials can be sourced within North America without the need for rare-earth elements.

“Successfully manufacturing our first battery cells is a pivotal moment in the journey of our battery technology,” said Dennis P. Calvert, President and CEO of BioLargo. “The testing and validation of these cells will allow us make claims about the capacity, charge/discharge rate, and other performance characteristics that we believe differentiate our batteries in the marketplace. After testing and validation, we will manufacture full-scale prototype Cellinity battery modules in 25- and 45-kilowatt hour capacities for further testing and validation.”

He continued, “In parallel to our ongoing development of the Cellinity battery, we’re exploring various financing options that ensure we get paid for and are in control of the engineering and construction of manufacturing facilities. Although initial discussions have taken place, we have no agreements in place. We believe a licensing and partnership model to be a better alternative to self-financed and self-operated manufacturing facilities competing with the likes of Tesla, and well suited for community-based manufacturing partners focused on underserved communities that are in special need of reliable renewable energy. Our target projects will add value to communities, develop workforces, stimulate economic development, promote grid stability and enable the development and expansion of micro-grids around the world. We will fundamentally enable and enhance the adoption of renewable energy.”

Mr. Calvert finished by saying, “The world needs a reliable, safe and eco-friendly alternative to lithium batteries, and we believe our Cellinity battery will meet these needs.”

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Friday 7 June 2024

BioLargo Engineering Secures Multi-Year Air Force Base Air Compliance Project







Westminster, CA – June 7, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that its engineering subsidiary has been awarded a contract to provide air quality services to three New Mexico U.S. Air Force (USAF) bases for up to five years, with a potential annual average revenue of $650,000.

The new contract is in addition to ongoing environmental support work at six Air Force bases and is the company’s largest dollar-value Air Force contract to date. These contracts provide regularly monthly flat fee revenue to the company over the life of the contract, which the Air Force may renew each year. BioLargo’s work at the New Mexico bases includes air quality regulatory compliance. Bhate Environmental Associates is the prime contractor with the Air Force under the Fence-to-Fence (F2F) support contract.

BioLargo Engineering, Science & Technologies President Randall Moore commented, “Our team has served Air Force bases with fence-to-fence air quality compliance services for years, but this is the largest such contract we’ve secured to-date. Larger, long-term contracts such as this one are crucial to our strategy of securing steady, reliable income from external clients. This empowers us to focus on commercializing BioLargo’s innovative cleantech technologies, including advancements in water treatment, energy storage, and air quality solutions.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

About Bhate Environmental Associates, Inc.

Bhate Environmental Associates, Inc. (Bhate) provides a diverse range of technical services in the environmental and infrastructure markets to the federal government and private industry. Headquartered in Birmingham, Alabama, Bhate’s reach is both national and global. At Bhate, we value high standards of safety, professionalism, ethics, and service to our clients. We foster a collaborative environment that encourages innovative ideas while providing challenges and rewards for our dedicated staff. Through our team’s Responsiveness, Integrity, and Teamwork, Bhate delivers professional, quality, cost-effective, and on-time results to our clients. See their website at www.Bhate.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.